Cardiology

Genetic test helps improve outcomes in heart stent patients

A genetic test recently implemented at UPMC Presbyterian can significantly reduce the risk of cardiovascular events by helping to identify more effective medication for some heart patients, according to the results of a large ...

Cardiology

Results from the BIONICS trial reported

The large multinational randomized BIONICS study found that a novel ridaforolimus-eluting stent (BioNIR) was non-inferior to a zotarolimus-eluting stent (Resolute) for one-year clinical outcomes in a broad, less selected ...

Cardiology

Lixisenatide doesn't affect cardiovascular risk in T2DM

(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...

Cardiology

Omega-3 fatty acids, xanthophylls don't cut CVD risk

(HealthDay)—Dietary supplementation with ω-3 polyunsaturated fatty acids or macular xanthophylls do not seem to reduce the risk of cardiovascular disease (CVD) in older adults with age-related macular degeneration, according ...

Diabetes

Metformin cuts cardio events in high-risk type 2 diabetes

(HealthDay)—Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

page 5 from 6